Back to News
Nov 10, 2025 12:00 PM

Eli Lilly Expands Genetic Eye-Disease Focused Pipeline With MeiraGTx Gene Therapy Collaboration

MeiraGTx Holdings plc (NASDAQ:MGTX) stock is trading higher after the company inked a strategic collaboration in the area of ophthalmology with Eli Lilly and Co. (NYSE:LLY).

MeiraGTx will grant Lilly worldwide exclusive rights to its AAV-AIPL1 program for Leber congenital amaurosis 4 (LCA4), an inherited eye disease that causes significant vision loss from birth.

Under the terms of the agreement, MeiraGTx will receive an upfront payment of $75 million and will be eligible to receive over $400 million in total milestone payments. The company is also eligible to receive tiered royalties on licensed products.

Clinical data from 11 children under 4 years old showed that all 11 blind children gained vision after treatment with AAV-AIPL1.

Beyond its effects on ...